339 related articles for article (PubMed ID: 24657054)
1. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
[TBL] [Abstract][Full Text] [Related]
2. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
Zaveri NT; Jiang F; Olsen C; Polgar WE; Toll L
Bioorg Med Chem Lett; 2013 Jun; 23(11):3308-13. PubMed ID: 23623415
[TBL] [Abstract][Full Text] [Related]
3. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists.
Meyer ME; Doshi A; Yasuda D; Zaveri NT
AAPS J; 2021 May; 23(3):68. PubMed ID: 33974173
[TBL] [Abstract][Full Text] [Related]
5. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.
Lin AP; Ko MC
ACS Chem Neurosci; 2013 Feb; 4(2):214-24. PubMed ID: 23421672
[TBL] [Abstract][Full Text] [Related]
7. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
Zaveri NT; Journigan VB; Polgar WE
ACS Chem Neurosci; 2015 Apr; 6(4):646-57. PubMed ID: 25635572
[TBL] [Abstract][Full Text] [Related]
8. Central N/OFQ-NOP Receptor System in Pain Modulation.
Kiguchi N; Ding H; Ko MC
Adv Pharmacol; 2016; 75():217-43. PubMed ID: 26920014
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.
Toll L; Khroyan TV; Polgar WE; Jiang F; Olsen C; Zaveri NT
J Pharmacol Exp Ther; 2009 Dec; 331(3):954-64. PubMed ID: 19773529
[TBL] [Abstract][Full Text] [Related]
10. Nociceptin/orphanin FQ receptor and pain: Feasibility of the fourth opioid family member.
Di Cesare Mannelli L; Micheli L; Ghelardini C
Eur J Pharmacol; 2015 Nov; 766():151-4. PubMed ID: 26277324
[TBL] [Abstract][Full Text] [Related]
11. Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics.
Ding H; Kiguchi N; Dobbins M; Romero-Sandoval EA; Kishioka S; Ko MC
Drugs; 2023 Jun; 83(9):771-793. PubMed ID: 37209211
[TBL] [Abstract][Full Text] [Related]
12. Discovery and structure-activity relationships (SAR) of a novel class of 2-substituted N-piperidinyl indole-based nociceptin opioid receptor ligands.
Meyer ME; Doshi A; Polgar WE; Zaveri NT
Bioorg Med Chem; 2023 Sep; 92():117421. PubMed ID: 37573822
[TBL] [Abstract][Full Text] [Related]
13. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
Tzschentke TM; Rutten K
Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
[TBL] [Abstract][Full Text] [Related]
14. Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.
Kiguchi N; Ding H; Kishioka S; Ko MC
Curr Top Med Chem; 2020; 20(31):2878-2888. PubMed ID: 32384033
[TBL] [Abstract][Full Text] [Related]
15. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic potentials of safe opioid analgesics targeting nociceptin/orphanin FQ peptide receptor].
Kiguchi N; Kishioka S; Ko MC
Nihon Yakurigaku Zasshi; 2021; 156(3):139-144. PubMed ID: 33952840
[TBL] [Abstract][Full Text] [Related]
17. Mechanical hyperalgesia in rats with diabetic polyneuropathy is selectively inhibited by local peripheral nociceptin/orphanin FQ receptor and µ-opioid receptor agonism.
Schiene K; Tzschentke TM; Schröder W; Christoph T
Eur J Pharmacol; 2015 May; 754():61-5. PubMed ID: 25697471
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomic study of the role of the nociceptin/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia.
Rutten K; Tzschentke TM; Koch T; Schiene K; Christoph T
Eur J Pharmacol; 2014 Oct; 741():264-71. PubMed ID: 25169429
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse.
Kiguchi N; Ding H; Ko MC
J Neurosci Res; 2022 Jan; 100(1):191-202. PubMed ID: 32255240
[TBL] [Abstract][Full Text] [Related]
20. Potential of Nociceptin/Orphanin FQ Peptide Analogs for Drug Development.
Wtorek K; Janecka A
Chem Biodivers; 2021 Jan; 18(1):e2000871. PubMed ID: 33351271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]